Tandem Diabetes Care, Inc. (NASDAQ: TNDM) may be approaching a major achievement in his business so we want to shed some light on the company. Tandem Diabetes Care, Inc., a medical device company, designs, develops, and markets a variety of products for people with insulin-dependent diabetes in the United States. The market cap company’s loss of $ 6.2 billion decreased as it announced a full fiscal year loss of $ 34 million, compared to its most recent loss of $ 25 million in the last twelve Months approaching breakeven. Many investors wonder how quickly Tandem Diabetes Care will turn a profit, with the big question being, “When will the company break even?” We have a brief rundown of what industry analysts expected for the company, break-even year, and the implied growth rate compiled.
Check out our latest analysis for Tandem Diabetes Care
Fifteen American medical device analysts agree that Tandem Diabetes Care is about to break even. They anticipate the company will make a final loss in 2020 before turning a positive profit of $ 10 million in 2021. Hence, the company is expected to break even in about 12 months or less. How fast does the company need to grow to hit the consensus estimates that predict breakeven in less than 12 months? Using a best-fit line, we calculated an average annual growth rate of 52%, which signals a high level of analyst confidence. Should the business grow more slowly, it will become profitable later than expected.
NasdaqGM: TNDM earnings per share growth June 28, 2021
Since this is a general overview, we won’t go into Tandem Diabetes Care’s upcoming projects, but keep in mind that a high projected growth rate is by and large not uncommon for a company currently in an investment phase.
What we want to bring to light with Tandem Diabetes Care is the relatively high level of debt. Typically, the debt shouldn’t exceed 40% of your equity, which in the case of Tandem Diabetes Care is 89%. Note that a higher debt obligation increases the risk of investing in the losing company.
Next Steps:
There are too many aspects of Tandem Diabetes Care to be covered in one short article, but the most important business fundamentals are all in one place – the Tandem Diabetes Care business page on Simply Wall St. We have a list of them too Important factors to research further:
- rating: What is Tandem Diabetes Care worth today? Is the future growth potential already factored into the price? The intrinsic value infographic in our free research report helps visualize whether Tandem Diabetes Care is currently being mispriced by the market.
- Management team: An experienced management team at the top strengthens our confidence in the business – see who sits on the board of directors of Tandem Diabetes Care and what the CEO’s background is.
- Other high performing stocks: Are there any other stocks that have a proven track record of offering better prospects? Discover our free list of these great stocks here.
Funded
When trading Tandem Diabetes Care or other investments, use the platform that is considered by many to be the professional’s gateway to the world market, Interactive Brokers. Get the cheapest * trading in stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.
This article from Simply Wall St is of a general nature. It is not a recommendation to buy or sell stocks and does not take into account your goals or your financial situation. Our goal is to provide you with long-term, focused analysis based on fundamentals. Note that our analysis may not take into account the latest company announcements or quality material, which is sensitive to the price. Simply Wall St has no position in the stocks mentioned.
* Interactive Brokers rated the cheapest broker by StockBrokers.com
Do you have any feedback on this article? Concerned about the content? Get in touch directly with us. Alternatively, send an email to the editorial team (at) simplywallst.com.
